Chinese Sle Treatment And Research Group

This pilot study tests Firsekibart, a biologic that blocks IL-1, in 15 adults with mild to moderate lupus who still have symptoms despite standard therapy. Participants receive three shots over 8 weeks, then stop the drug to see if symptoms return. The goal is to see if this appr…

This phase 3 trial tests whether adding sirolimus (rapamycin) to standard treatment helps control active lupus better than placebo. 146 adults with active lupus despite standard care will receive either sirolimus or placebo for 24 weeks, with an option to continue for another 24 …